



DAFTAR PUSTAKA

- American cancer society. (2021). Ovarian Cancer Risk Factors. <https://www.cancer.org/cancer/ovarian-cancer/causes-risks-prevention/risk-factors.html>
- Aurora, T., Mullangi, S., Lekkala, M. R. (2022). Ovarian Cancer. Treasure Island (FL) : Stat Pearls Publising LLC
- Avsar, H. A., Kurt, Sefa., Celiloglu, Murat., dan Timur, Tunc. Diagnostic use of CA 125 values measured on THE 2nd and 14th days of the menstrual cycle in endometriosis. *J Surg Med.* 2022. 6(5):586-590. doi:10.28982/josam.988164
- Ballehaninna, U. K. dan Chamberlain, R. S. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. *J Gastrointest Oncol.* 2012. vol 3(2), 105-119. doi:10.3978/j.issn.2078-6891.2011.021
- Barbolina, M. V. Molecular Mechanisms Regulating Organ-Specific Metastases in Epithelial Ovarian Carcinoma. Multidisciplinary Digital Publishing Institute. *Cancers (Basel).* 2018. vol 10(11), 444. doi:10.3390/cancers10110444
- Berek, J. S., Renz, M., Kehoe, S., Kumar, L., Friedlande, M. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. *Int J Gynecol Obstet.* 2021; 55(Suppl. 1):61–85. doi:10.1002/ijgo.13878
- Bottoni, P., & Scatena, R. The Role of CA 125 as Tumor Marker: Biochemical and Clinical Aspects. *Adv Exp Med Biol.* 2015. 229–244. doi:10.1007/978-94-017-7215-0_14
- Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics. *GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin.* 2018. 68(6):394-424. doi:10.3322/caac.21492



- Charkhchi, P., Cybulski, C., Gronwald, J., Wong, F. O., Narod, S. A., & Akbari, M. R. CA 125 and Ovarian Cancer: A Comprehensive Review. *Cancers (Basel)*. 2020. 12(12), 3730. doi:10.3390/cancers12123730
- Chornokur G, Amankwah EK, Schildkraut JM, Phelan CM. Global ovarian cancer health disparities. *Int J Gynecol Oncol*. 2013. 129(1):258-264. doi:10.1016/j.ygyno.2012.12.016
- Coburn S, Bray F, Sherman M, Trabert B. International patterns and trends in ovarian cancer incidence, overall and by histologic subtype. *Int J Cancer*. 2017. 140(11):2451-2460. doi:10.1002/ijc.30676
- Davidson, Fiona. Guidelines for CEA Requesting. *NHS J*. 2012. Version 7, 1-2
- Dochez, V., Caillon, H., Vaucel, E., Dimet, J., Winer, N., & Ducarme, G. Biomarkers and algorithms for diagnosis of ovarian cancer: CA125, HE4, RMI and ROMA, a review. *J Ovarian Res*. 2019. 12:28. doi:10.1186/s13048-019-0503-7
- Doubeni, C. A., Doubeni, A. R., Myers, A. E. Diagnosis and Management of Ovarian Cancer. *AAFP* . 2016. vol 93, 937-944. <https://www.aafp.org/dam/brand/aafp/pubs/afp/issues/2016/0601/p937.pdf>
- Ferris, J. S., Daly, M. B., Buys, S. S., Genkinger, J. M., Liao, Y., & Terry, M. B. Oral contraceptive and reproductive risk factors for ovarian cancer within sisters in the breast cancer family registry. *Br J Cancer*. 2014. 110(4), 1074-1080. doi:10.1038/bjc.2013.803
- Hall, C., Clarke, L., Pal, A., Buchwald, P., Eglinton, T., Wakeman, C., Frizelle, F. A Review of the Role of Carcinoembryonic Antigen in Clinical Practice. *Ann Coloproctol*. 2019. 35(6), 294-305. doi:10.3393/ac.2019.11.13
- Holdenrieder, S., Pagliaro, L., Morgenstern, D., & Dayyani, F. Clinically Meaningful Use of Blood Tumor Markers in Oncology. *Biomed Res Int*. 2016. doi:10.1155/2016/9795269
- Howe, T., Sokolovsky, N., Sayasneh, A., Omar, K., & Tahmasebi, F. Raised CA125 – what we actually know. *TOG*. 2020. 23(1), 21-27. doi:10.1111/tog.12704



- Huang, J., Chan, W.C., Ngai, C.H., Lok, V., Zhang, L., Lucero-Prisno, D.E., III; Xu, W., Zheng, Z.-J, Elcarte, E., Withers, M., et al. Worldwide Burden, Risk Factors, and Temporal Trends of Ovarian Cancer: A Global Study. *Cancers (Basel)*. 2022. 14(9), 2230. doi:10.3390/cancers14092230
- Huy, N. V. Q., Van Khoa, V., Tam, L. M., Vinh, T. Q., Tung, N. S., Thanh, C. N., & Chuang, L. Standard and optimal cut-off values of serum ca-125, HE4 and ROMA in preoperative prediction of ovarian cancer in Vietnam. *Gynecol Oncol Rep*. 2018. 110–114. doi:10.1016/j.gore.2018.07.002
- Kim SJ, Rosen B, Fan I, et al. Epidemiologic factors that predict long-term survival following a diagnosis of epithelial ovarian cancer. *Br J Cancer*. 2017. 116(7):964-971. doi: 10.1038/bjc.2017.35.
- Madsen, C., Baandrup, L., Dehlendorff, C., Kjaer, S. K. 2014. Tubal ligation and salpingectomy and the risk of epithelial ovarian cancer and borderline ovarian tumors: a nationwide case-control study. *Acta Obstet Gynecol Scand*. 2015. 94(1):86-94. doi:10.1111/aogs.12516
- Mitra, A. K. (2016). Ovarian Cancer Metastasis: A Unique Mechanism of Dissemination. *Tumor Metastasis*. Chapter 3. China : Tianjin Medical University General Hospital. 266. doi:10.5772/64700
- Momenimovahed, Z., Tiznobaik, A., Taheri, S., & Salehiniya, H. Ovarian cancer in the world: epidemiology and risk factors. *Int J Women's Health*. 2019. Vol 11, 287–299. doi:10.2147/ijwh.s197604
- Nagai, T., Oshiro, H., Sagawa, y., Sakamaki, K., Terauchi, F., and Nagao, T. Pathological Characterization of Ovarian Cancer Patients Who Underwent Debulking Surgery in Combination With Diaphragmatic Surgery. *Medicine (Baltimore)*. 2015. 94(50):e2296. doi:10.1097/MD.0000000000002296
- Nagar, H. (2018). The Role of Lymphadenectomy in Ovarian Epithelial Cancer. *Ovarian Cancer - From Pathogenesis to Treatment*. doi:10.5772/intechopen.72702



- Orskov M, Lachina M, Guldborg R, Mogensen O, Nørgård BM. Predictors of mortality within 1 year after primary ovarian cancer surgery: a nationwide cohort study. *BMJ Open*. 2016. 6(4):e010123.
doi:10.1136/bmjopen-2015-010123
- Poole, E. M., Merritt, M. A., Jordan, S. J., Yang, H. P., Hankinson, S. E., Park, Y., Tworoger, S. S. Hormonal and Reproductive Risk Factors for Epithelial Ovarian Cancer by Tumor Aggressiveness. *Cancer Epidemiol Biomarkers Prev*. 2013. 22(3), 429–437.
doi:10.1158/1055-9965.epi-12-1183-t
- Poruk, K. E., Gay, D. Z., Brown, K., Mulvihill, J. D., Boucher, K. M., Scaife, C. L., Firpo, M. A., and Mulvihill, S. J. The Clinical Utility of CA 19-9 in Pancreatic Adenocarcinoma: Diagnostic and Prognostic Updates. *Curr Mol Med*. 2013. volume 13, 340-351. doi:10.2174/1566524011313030003
- Shannon, N. B., Tan, G. h. c., Chia, C. S., Soo, K. C., Teo, M. C. C. *CA-125*: an inaccurate surveillance tool immediately after cytoreductive surgery and hyperthermic intraoperative chemotherapy (CRS-HIPEC)? *Int J Hyperthermia*. 2017. 34(5), 1–4. doi:10.1080/02656736.2017.1342874
- Siegel RL, Miller KD, Jemal A. Cancer statistics. *CA Cancer J Clin*. 2017. 67(1): 7-30. doi: 10.3322/caac.21387.
- Sieh W, Salvador S, McGuire V, et al. Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies. *Int J Epidemiol*. 2013. 42(2):579-89. doi: 10.1093/ije/dyt042
- Sørensen. C. G., Karlsson. W. K., Pommergaard. H. C., Burchardt. J., Rosenberg. J. The diagnostic accuracy of carcinoembryonic antigen to detect colorectal cancer recurrence – A systematic review. *IJS*. 2016. 25, 134-144. doi:10.1016/j.ijssu.2015.11.065
- Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, Gaudet MM, Jemal A, Siegel RL. Ovarian cancer statistics. *CA Cancer J Clin*. 2018 68(4):284-296. doi: 10.3322/caac.21456